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AbstrAct
In chronic stable angina, elevated heart rate contributes 
to the development of symptoms and signs of myocardial 
ischaemia by increasing myocardial oxygen demand 
and reducing diastolic perfusion time. Accordingly, heart 
rate reduction is a well-known strategy for improving 
both symptoms of myocardial ischaemia and quality of 
life (QOL). The heart rate-reducing agent ivabradine, a 
direct and selective inhibitor of the I
f current, decreases 
myocardial oxygen consumption while increasing diastolic 
time, without affecting myocardial contractility or coronary 
vasomotor tone. Ivabradine is indicated for treatment of 
stable angina and chronic heart failure (HF). This review 
examines available evidence regarding the efficacy and 
safety of ivabradine in stable angina, when used as 
monotherapy or in combination with beta-blockers, in 
particular angina subgroups and in patients with stable 
angina with left ventricular systolic dysfunction (LVSD) or 
HF. Trials involving more than 45 000 patients receiving 
treatment with ivabradine have shown that this agent 
has antianginal and anti-ischaemic effects, regardless 
of age, sex, severity of angina, revascularisation status 
or comorbidities. This heart rate-lowering agent might 
also improve prognosis, reduce hospitalisation rates and 
improve QOL in angina patients with chronic HF and LVSD.
IntroduCtIon
Heart rate is one of the main determinants 
of myocardial oxygen consumption and, 
under normal circumstances, an increase in 
heart rate is mirrored by a parallel increase 
in coronary blood flow.1 Elevated heart rate 
shortens the length of each cardiac cycle, 
reducing diastolic perfusion time and thus 
oxygen supply.1 Elevated heart rate may also 
enhance the development of atherosclerosis, 
according to animal data, by increasing the 
exposure of the endothelium to shear stress.2 
The pathogenesis of chronic stable angina 
is complex but basically implies an imbal-
ance between myocardial oxygen supply 
and demand. An elevated heart rate plays 
an important role in the development of 
myocardial ischaemia and angina as a result 
of increased myocardial oxygen demand and 
a reduction in diastolic perfusion time, the 
latter being of particular importance consid-
ering that 90% of coronary flow occurs in 
diastole. In patients with elevated heart rates, 
shortened diastolic duration and impaired 
collateral flow lead to reduced tissue perfu-
sion in myocardial regions downstream of 
stenoses.3 4 In these regions, myocardial 
blood flow and contractility are impaired.4–6
This review article will focus on the use of 
ivabradine, a drug that selectively reduces 
heart rate for the treatment of stable 
angina pectoris in different clinical condi-
tions, including patients with preserved or 
impaired left ventricular (LV) function. 
By reducing heart rate without affecting 
myocardial inotropic function or coronary 
vasomotor tone, ivabradine reduces oxygen 
demand and maintains diastolic time.7 
Longer diastole and higher collateral pres-
sure enhance coronary flow and contrac-
tility in ischaemic myocardium.8–11 This 
review explores existing evidence from both 
randomised clinical trials and real-world clin-
ical data regarding the role of ivabradine 
for management of stable angina pectoris in 
patients with and without LV dysfunction and 
other comorbidities. Although important for 
clinical decision making, we do not—in the 
present manuscript—discuss reimbursement 
status or cost effectiveness, given the limited 
data available on the topic.
IvabradIne: ClInICal pharmaCology
pharmacokinetic properties
Under physiological conditions, ivabradine 
is rapidly released from tablets and quickly 
and almost completely absorbed after oral 
administration. Under fasting conditions, it 
reaches peak plasma levels in approximately 
1 hour. Taking ivabradine during meals 
reduces intraindividual variability in absorp-
tion time. Ivabradine is metabolised by both 
the liver and the gut by oxidation through 
cytochrome P450 3A4 (CYP3A4). This agent 
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has low affinity for CYP3A4 and does not seem to modify 
CYP3A4 substrate metabolism or plasma concentrations. 
Potent inhibitors and inducers of CYP3A4, however, may 
affect the plasma levels of ivabradine. It is for this reason 
that ivabradine must not be coprescribed with strong 
or moderate CYP3A4 inhibitors, such as diltiazem and 
verapamil. Ivabradine’s main half-life is approximately 
2 hours (70%–75% of the AUC) and its effective half-life 
around 11 hours. Of clinical importance, ivabradine can 
be safely combined with first-line pharmacological agents 
commonly used to improve outcome in the manage-
ment of cardiovascular disease such as aspirin, statins, 
beta-blockers and renin–angiotensin–aldosterone system 
inhibitors, as well as antidiabetic agents, proton pump 
inhibitors and antidepressant agents.
pharmacodynamic effects
In humans, at the currently recommended doses, heart 
rate reduction—the main pharmacodynamic property 
of ivabradine—is approximately 10 bpm both at rest 
and during exercise. A study in 23 healthy volunteers 
(aged 19–63 years) using ivabradine 7.5 mg twice daily 
demonstrated a significant reduction in heart rate over 
24 hours, without affecting circadian heart rate patterns 
(figure 1).12
Of major importance in clinical practice and partic-
ularly in subjects with comorbidities, ivabradine does 
not influence intracardiac conduction, contractility or 
ventricular repolarisation nor does it affect central aortic 
pressure (or LV afterload).13 Studies have reported no 
effects of ivabradine on atrioventricular or intraventric-
ular conduction times or corrected QT interval.14
mechanisms of action
Under physiological circumstances, heart rate is deter-
mined by the rate of spontaneous diastolic depolarisation 
in the sinoatrial node.15 Spontaneous diastolic depolarisa-
tion is influenced by a mixed sodium–potassium current 
(If) across f-channels. If is directly and selectively inhibited 
by ivabradine, which results in reduced diastolic depolar-
isation rates and the slowing of heart rate (figure 2).16–19 
Ivabradine enters—and blocks—the f-channel from 
the cytoplasmic side of the cell membrane and does it 
mainly when the channel is in the open state.17 It has 
been reported that this blocking action reduces the rate 
of pacemaker activity of the heart, which is more intense 
at a higher firing rate, as suggested by different groups 
of investigators.17 20 21 Ivabradine, therefore, is a specific 
heart rate-reducing drug. Indeed, its specificity for the 
If current guarantees that this compound has no direct 
effects on myocardial function, ventricular repolarisation 
or cardiac conduction.22 23 Of importance, ivabradine’s 
specific mode of action limits its use to patients with sinus 
rhythm and excludes patients in atrial fibrillation or atrial 
flutter.
Many studies in humans—including both healthy 
volunteers and patients24–26—have shown that heart rate 
reduction with ivabradine largely depends on the dose 
used and the individual’s baseline heart rate. In a 6-month 
Holter substudy of the morBidity-mortality EvAlUaTion 
Figure 1 Change from baseline in mean heart rate over 24 hours after treatment with ivabradine 7.5 mg twice daily in 
volunteers. Clinical data from the Institut de Recherches Internationales Servier (IRIS) database. EudraCT record 2011-001665-
40 (data on file). bid, twice a day; bpm, beats per minute. Copied from reference: Deedwania 2013.12
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of the If inhibitor ivabradine in patients with coronary 
disease and left-ventricULar dysfunction (BEAUTIFUL) 
trial, involving patients with stable coronary artery disease 
(CAD) and left ventricular systolic dysfunction (LVSD),27 
treatment with ivabradine reduced 24 hours heart rate 
by 6.3±9.5 beats per minute (bpm) compared with no 
demonstrable changes in patients receiving placebo 
(0.4±7.2 bpm, P<0.001). Of interest, this study showed 
that heart rate reduction during waking hours in patients 
receiving treatment with ivabradine was greater than 
the heart rate reduction achieved during night sleep 
(6.8±10.4 vs 5.2±8.9 bpm). Ivabradine per se rarely trig-
gers severe bradycardia when used at the recommended 
doses.
INternatIonal TrIal of the AnTi-anginal effects of 
IVabradinE (INITIATIVE compared with atenolol), 
involving 939 patients with stable angina, showed that 
ivabradine reduced heart rate both at rest and at peak 
exercise.28 In a randomised, double-blind study in 
386 patients with stable angina receiving treatment with 
ivabradine (5 mg or 7.5 mg twice daily) for 1 year,29 heart 
rate reduction with this agent was shown to be sustained 
over time. Another study showed that heart rate reduc-
tion triggered by ivabradine is greatest in those patients 
with the highest pretreatment baseline heart rate.30 
Investigations on the role of ivabradine in cardiovascular 
medicine have shown that this agent has beneficial effects 
on blood vessels, coronary disease progression and the 
myocardium (figure 2).19 These effects are likely to be 
related to the heart rate-reducing actions of this drug, 
although ivabradine may have pleiotropic effects unre-
lated to its actions on heart rate.
IvabradIne In treatment of stable angIna peCtorIs
Improving both symptoms of myocardial ischaemia and 
quality of life (QOL) are major goals in the treatment 
of stable angina pectoris.31 A large body of evidence on 
the efficacy and safety of ivabradine for the symptomatic 
therapy of stable angina has accumulated over the past 
years (table 1).11 12 24 26 28 29 32–50 Nearly 5000 patients with 
angina have been included in randomised clinical trials 
and nearly 11 000 angina patients have been included in 
open, observational studies assessing the antianginal effi-
cacy of ivabradine.
Ivabradine as monotherapy in angina
In a placebo-controlled, randomised, dose-ranging 
study in 360 patients with stable CAD and chronic stable 
angina, Borer et al24 showed that ivabradine improved—
in a dose-dependent fashion—exercise stress testing vari-
ables. In this study, ivabradine given twice daily improved 
the time to 1 mm ST-segment depression compared with 
placebo (P=0.016) and other important variables in a 
dose-dependent manner.24 In an open-label extension 
phase spanning over 2–3 months in this study, ivabra-
dine-reduced angina attacks from 4.14 to 0.95 attacks per 
week (P<0.001) and the use of short-acting nitrates from 
2.28 to 0.50 units per week (P<0.001).24
Figure 2 Cardioprotective effects of ivabradine administration in the setting of acute coronary syndromes and myocardial 
infarction. HR, heart rate; hsCRP, high sensitivity C reactive protein; LVEF, left ventricular ejection fraction; MI, myocardial 
infarction; NO, nitric oxide; ROS, reactive oxygen species; VF, ventricular fibrillation; VT, ventricular tachycardia. Copied from 
reference: Niccoli et al.19
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Table 1 Summary of the clinical data on ivabradine in patients with stable angina with or without left ventricular systolic 
dysfunction or heart failure
Effects of ivabradine on symptoms/myocardial ischaemia in patients with stable angina
Publication Study summary
Stable angina – monotherapy
  Borer et al24
  (n=360)
Randomised, double-blind, placebo-controlled, multicentre study in patients with chronic SA 
(n=360). Duration: 2 wks double-blind+2–3 months open-label. Efficacy: TST and TLA. At 2 
wks, TST increased by 32.0 and 44.1 s with ivabradine 2.5 mg and 5 mg twice daily versus 
9.0 s with placebo (P=0.016 for 5 mg twice daily dose vs placebo). TLA increased by 22.5 s 
and 27.2 s with ivabradine 2.5 and 5 mg twice daily versus 12.7 s with placebo. Resting HR 
and exercise HR decreased significantly with ivabradine 2.5 mg and 5 mg twice daily (both 
P<0.05 vs placebo).
  INITIATIVE, 200528
  (n=939)
Randomised, double-blind, parallel-group, multicentre study in patients with SA. Duration: 
16 wks. Efficacy: TED during ETT. Change in TED at trough: +86.8 s with ivabradine 
7.5 mg twice daily versus +78.8 s with atenolol 50–100 mg/day (mean difference 10.3 s; 
P<0.001 for non-inferiority). Change in the number of angina attacks/wk at 16 wks: −2.2 for 
ivabradine 7.5 mg twice daily versus −2.7 mg for atenolol. Change in resting HR: −14.3 bpm 
for ivabradine 7.5 mg twice daily versus −15.6 bpm for atenolol.
  Ruzyllo et al32
  (n=1195)
Randomised, double-blind, parallel-group, multicentre study in patients with chronic 
SA. Duration: 3 months. Efficacy: TED during ETT. Change in TED at trough: +27.6 s with 
ivabradine 7.5 mg twice daily versus +31.2 s with amlodipine 10 mg od (mean difference 
1.8 s; P<0.001 for non-inferiority). Change in the number of angina attacks/wk: −3.0 for 
ivabradine 7.5 mg twice daily versus −3.0 for amlodipine.
  Skalidis et al33
  (n=21)
Prospective, open single-centre study in patients with stable CAD of one or two vessels, 
who were eligible for PCI. Duration: 1 wk. Efficacy: ivabradine 5 mg twice daily improved 
hyperaemic coronary flow velocity and reserve in patients with stable CAD. Resting-APV 
(17.0±5.5 vs 19.7±7.6, P=0.003) and augmentation of hyperaemia-APV (57.9±17.8 vs 
53.5±21.4, P=0.009) led to improvement in CFR (3.51±0.81 vs 2.78±0.61, P<0.001).
  Tagliamonte et al34
  (n=59)
Prospective, randomised, double-blind trial in patients with stable CAD. Duration: 1 month. 
Efficacy: coronary flow velocity reserve increased significantly with ivabradine 2.5–7.5 mg 
twice daily (3.52±0.64 vs 2.67±0.55, P<0.001) and bisoprolol 2.5–10 mg od (3.35±0.70 vs 
2.72±0.55, P<0.001), but it was significantly greater with ivabradine. HR decreased similarly 
(63±7 vs 61±6 bpm; P=NS).
  Gloekler et al11
  (n=46)
Prospective, randomised, placebo-controlled, monocentre, proof-of-concept trial in 46 
patients with chronic stable CAD, 23 of whom received placebo and 23 ivabradine for 
6 months. HR changed by +0.2 bpm with placebo and −8.1 bpm with ivabradine (P=0.0089). 
With placebo, collateral flow index decreased from 0.140 at baseline to 0.109 at follow-up 
(P=0.12), while it increased from 0.107 to 0.152 with ivabradine (P=0.0461).
  Maranta et al35
  (n=15)
An open-label, proof-of-concept study in 15 patients with exercise-inducible ischaemia. 
Stress echocardiography was done at baseline after washout and repeated after 2 wks 
of ivabradine 7.5 mg twice daily at the same workload. Ivabradine reduced both acute LV 
dysfunction and stunning in CAD patients with exercise-induced ischaemia.
  REDUCTION 200936
  (n=4954)
Multicentre, open-label, observational study in patients with SA pectoris. Duration: 4 months. 
Ivabradine 2.5–7.5 mg twice daily+BB. Change in resting HR: −12.4 bpm (P<0.0001 vs 
baseline). Change in the number of angina attacks/wk: from 2.8 to 0.5 (P<0.0001 vs 
baseline). Change in the consumption of nitrates: from 3.7 to 0.7 U (P<0.0001 vs baseline).
Stable angina – in combination
  ASSOCIATE, 200937
  (n=889)
Randomised, double-blind, placebo-controlled, multicentre study in patients with chronic 
SA. Duration: 4 months. Ivabradine 5–7.5 mg twice daily+atenolol 50 mg od versus 
placebo+atenolol 50 mg od. Efficacy: TED during ETT. Change in TED at trough: +24.3 s 
versus +7.7 s (P<0.001). Change in TLA: +26.0 s versus +9.4 s (P<0.001). Change in 
TAO:+49.1 s versus +22.7 s (P<0.001). Change in TST: +45.7 s versus +15.4 s (P<0.001).
  ADDITIONS 201238
  (n=2330)
Multicentre, open-label, observational study in patients with SA. Duration: 4 months. 
Ivabradine 2.5–7.5 mg twice daily+BB. Change in resting HR: from 85.0 bpm to 65.6 bpm 
(P<0.0001 vs baseline). Change in the number of angina attacks/wk: −1.4 (P<0.0001 vs 
baseline). Change in the consumption of nitrates: −1.9 U (P<0.0001 vs baseline).
Continued
group.bmj.com on March 9, 2018 - Published by http://openheart.bmj.com/Downloaded from 
5Kaski JC, et al. Open Heart 2018;5:e000725. doi:10.1136/openhrt-2017-000725
Coronary artery disease
Effects of ivabradine on symptoms/myocardial ischaemia in patients with stable angina
Publication Study summary
  López-Bescós et al29
  (n=386)
Randomised, double-blind, parallel-group, multicentre study in patients with chronic SA on 
concomitant therapy (excluding BBs). Duration: 12 months. Ivabradine 5 mg or 7.5 mg twice 
daily. Change in resting HR: −9.7 and −12.3 bpm. Change in the number of angina attacks/
wk: −1.9 and −1.2. Change in the consumption of nitrates: −1.2 U and −1.7 U.
  Pooled analysis by Werdan39
  (n=8555)
Pooled data from three observational clinical studies in 8555 patients with SA received 
2.5 mg, 5 mg or 7.5 mg twice daily of ivabradine for 4 months. Therapy with ivabradine was 
associated with a significant reduction in the frequency of angina attacks and consumption 
of short-acting nitrates of 87%. Ivabradine is effective and safe in all subpopulations of 
angina patients seen in clinical practice, independent of age, comorbidities and use of BBs.
  Panhellenic study, 201540
  (n=2403)
Observational, prospective, open-label study in 2403 patients with chronic SA receiving 
ivabradine 5–7.5 mg twice daily for 4 months in combination with BBs. Ivabradine reduced 
resting HR from 81.5±9.7 bpm to 63.9±6.0 bpm (P<−0.001), mean number of anginal 
attacks decreased from 2.0±2.0 times/wk to 0.2±0.6 times/wk (P<0.001) and nitroglycerin 
consumption decreased from 1.4±2.0 times/wk to 0.1±0.4 times/wk (P<0.001). The 
percentage of patients with CCS angina class I increased from approximately 38% (baseline) 
to 84% (study completion; P<0.001). The mean EQ-5D visual analogue scale index increased 
by 16.1 points (P<0.001), and compliance with treatment was high throughout the trial 
(96%).
Stable angina – special populations
  Elderly – REDUCTION, 201142
  (n=382)
Multicentre, open-label, observational study in elderly patients (≥80 years old) with SA. 
Duration: 4 months. Ivabradine 2.5–7.5 mg twice daily+BBs. Change in resting HR: −12.0 
bpm (P<0.0001 vs baseline). Change in the number of angina attacks/wk: from 3.0 to 0.8 
(P<0.0001 vs baseline). Change in the consumption of short-acting nitrates: from 4.2 U to 
1.2 U (P<0.0001 vs baseline).
  Elderly – ADDITIONS, 201443
  (n=479)
Retrospective analysis of observational, multicentre, prospective, open-label ADDITIONS 
study investigating ivabradine twice daily+BB in SA patients ≥75 years. Duration: 4 months. 
Efficacy: HR fell by 19.2±11.6 bpm to 65.4±8.3 bpm. Frequency of angina attacks diminished 
by 1.6±1.8/wk to 0.4±1.3/wk and consumption of short-acting nitrates fell by 2.2±3.2 units/
wk to 0.6±1.8 units/wk (both P<0.0001). Severity of angina, according to CCS grade, 
decreased and QOL improved (P<0.0001).
  Pooled analysis from RCTs, 200926
  (n=2425)
Pooled analysis of five randomised, double-blind, parallel-group studies in patients with SA. 
Duration: 3–4 months. Ivabradine ≥5 mg twice daily. Change in resting HR: −14.5% (11.3 
bpm) in all patients; reduction of 12.4%–16.3% in subpopulations (no difference between 
groups). Change in the number of angina attacks/wk: −59.4% in all patients; reduction of 
51%–70% in subpopulations (no difference between groups). Change in the consumption of 
nitrates: −53.7% in all patients; reduction of 0.4 to 3.4 U/wk in subpopulations.
  Diabetes, 201044
  (n=2907)
Pooled analysis of eight multicentre, randomised, double-blind studies in patients with 
SA. Duration: 2 wks–1 year. Change in resting HR: −11.3 bpm in patients without diabetes 
mellitus versus −11.6 bpm in patients with diabetes mellitus. Change in the number of 
angina attacks/wk: −2.2 in patients without diabetes mellitus versus −2.0 in patients with 
diabetes mellitus.
  Postrevascularisation – post hoc analysis from 
ADDITIONS, 201545
  (n=1193)
Observational, multicentre prospective study in patients with SA on BBs treated with 
ivabradine at standard doses. Duration: 4 months. In post-PCI patients, ivabradine decreased 
HR from 83.1 to 64.4 bpm (P<0.0001). Number of angina attacks decreased from 1.9/wk to 
0.5/wk. Frequency of nitroglycerin fell from 2.7 times/wk to 1.0 times/wk.
  Postrevascularisation – post hoc analysis of the 
Panhellenic study, 201746
  (n=926)
Post hoc analysis of postrevascularisation patients in a prospective, observational study of 
2403 patients with SA with CAD taking optimised BB therapy. Duration: 4 months. Treatment 
with ivabradine reduced angina attacks from 2.2/wk to 0.3/wk (P<0.001) and nitroglycerin 
consumption from 1.5 times/wk to 0.1 times/wk (P<0.001). QOL improved versus baseline 
(P<0.001).
  Postrevascularisation – RIVENDEL study, 201747
  (n=70)
Prospective, randomised controlled, open-label study examining the addition of ivabradine 
(up to 7.5 mg twice daily) to standard medical therapy in CAD patients >30 days after PCI. 
Duration: 8 wks. Addition of ivabradine to standard therapy reduced HR from 68.0 bpm to 
62.2 bpm (P<0.001), improved flow-mediated dilation from 8.7 to 15.0 (P<0.001) and 
enhanced nitroglycerin-mediated dilation from 12.7 to 17.7 (P<0.001).
Table 1 Continued 
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The anti-ischaemic effects of ivabradine were compared 
with those of the beta-blocker atenolol in the INITIATIVE 
study.28 The study revealed that after 16 weeks of treat-
ment, patients in the ivabradine group (receiving 7.5 mg 
twice daily) and those receiving atenolol (100 mg/day) 
had similar beneficial effects on total exercise duration 
and the number of angina attacks per week (−2.2±4.3 vs 
−2.7±12.3).28 In addition to ivabradine’s non-inferiority 
in this study, data at 4 months of follow-up showed that 
all stress test variables, including time to limiting angina, 
time to angina onset and time to 1 mm ST-segment 
depression, showed a tendency to a larger improvement 
with ivabradine compared with atenolol. Ivabradine 
reduced heart rate by 14.3 bpm compared with a 15.6 
bpm reduction achieved with atenolol.28
Ivabradine’s anti-ischaemic effects were also compared 
with those of amlodipine (10 mg once daily) in a multi-
centre, double-blind, randomised, parallel-group trial 
involving 1195 patients with stable angina pectoris.32 In 
this study, ivabradine was non-inferior to amlodipine 
regarding exercise capacity, time to onset of angina, time 
to limiting angina, time to 1 mm ST-segment depression, 
on stress testing and prevention of daily life angina attacks 
or nitrate use. Ivabradine administration resulted in a 
larger reduction in heart rate–blood pressure product, 
a marker for myocardial oxygen consumption, than 
amlodipine.32
Whether ivabradine (5 mg twice daily) can improve 
coronary flow reserve (CFR) was assessed by Skalidis 
et al33 in 21 patients with stable angina. Coronary blood 
Effects of ivabradine on symptoms/myocardial ischaemia in patients with stable angina
Publication Study summary
Effects of ivabradine on outcomes in patients with stable CAD
  SIGNIFY, 201448
  (n=19 102)
Randomised, double-blind, placebo-controlled trial of ivabradine, added to standard therapy, 
in patients with stable CAD without clinical HF and HR ≥70 bpm. Ivabradine up to 10 mg 
twice daily versus placebo. Duration: 27.8 months (median). Efficacy: no difference in the 
incidence of the primary endpoint (a composite of death from CV causes or non-fatal MI) 
between the ivabradine and placebo groups (6.8% and 6.4%, respectively; HR: 1.08; 95% CI 
0.96 to 1.20; P=0.20).
Effects of ivabradine in patients with LVSD with and without HF
  Amosova et al49
  (n=29)
Randomised, parallel-group, single-blind study in patients with SA and moderate LVSD. 
Duration: 2 months. Ivabradine 5–7.5 mg twice daily+bisoprolol 5 mg od versus bisoprolol 
5–10 mg od. Change in mean resting HR: from 76.6 bpm to 59.3 bpm (P<0.001 vs baseline) 
versus from 75.9 bpm to 60.5 bpm (P=0.002 vs baseline). Change in 6 min walking test 
distance: from 388 m to 446 m (P<0.001 vs baseline) versus from 386 m to 400 m (P=NS). 
Angina attacks were reduced from 3.3±1.1 to 1.7±0.6 in the ivabradine group and from 
3.2±1.0 to 2.5±0.9 in the bisoprolol-alone group (intergroup P=0.041).
  Angina subgroup analysis from BEAUTIFUL, 200950
  (n=1507)
Post hoc analysis in patients with SA and LVEF <40% from a randomised, double-blind, 
placebo-controlled, multicentre study. Duration: 19 months (median). Ivabradine 5–7.5 mg 
twice daily versus placebo. Efficacy: composite endpoint of CV death, admission to hospital 
for acute MI and admission to hospital for new-onset or worsening HF. Primary endpoint: 
24% RRR (P=0.05). Hospitalisation for MI: 42% RRR (P=0.021). In patients with HR ≥70 bpm: 
hospitalisation for MI: 73% RRR (P=0.002); coronary revascularisation: 59% RRR.
  Angina subgroup analysis from SHIFT, 201756
  (n=2220)
Post hoc analysis in patients with SA and chronic HF (LVEF ≤35%) from a randomised, 
double-blind, placebo-controlled, multicentre study in adults in sinus rhythm with stable. 
Duration: 22.9 months (median). Ivabradine up to 7.5 mg twice daily versus placebo. Efficacy: 
composite endpoint of CV death or non-fatal MI reduced by 8% versus placebo (P=NS) 
compared with 11% and 11% in patients without angina and in the overall population, 
respectively.
Modified from reference: Deedwania.12
ADDITIONS, prActical  Daily efficacy and safety of procoralan In combinaTION with beta blockerS; APV, time-averaged peak flow 
velocity; ASSOCIATE, evaluation of the Antianginal efficacy and Safety of the aSsociation Of the If Current Inhibitor ivAbradine with a 
beTa-blockEr; BB, beta-blocker; bid, twice daily; bpm, beats per minute; BEAUTIFUL, morBidity-mortality EvAlUaTion of the If inhibitor 
ivabradine in patients with coronary disease and left-ventricULar dysfunction; CAD, coronary artery disease; CCS, Canadian Cardiovascular 
Society; CFR, coronary flow reserve; CV, cardiovascular; EQ-5D, EuroQol five dimensions questionnaire; ETT, exercise tolerance test; HF, 
heart failure; HR, heart rate;INITIATIVE; INternatIonal TrIal of the AnTi-anginal effects of IVabradinE; LV, left ventricular; LVEF, left ventricular 
ejection fraction; LVSD, left ventricular systolic dysfunction; MI, myocardial infarction; NS, not significant; od, once daily; PCI, percutaneous 
coronary intervention; QOL, quality of life; REDUCTION, Reduction of  ischemic   events by reduction of  heart rate in the treatment of stable 
angina with ivabradine; RIVENDEL, Heart Rate reduction by IVabradine for improvement of ENDothELial function in patients  with coronary 
artery disease; RRR, relative risk reduction; SA, stable angina; SIGNIFY, Study assessInG the morbidity-mortality beNefits of the If inhibitor 
ivabradine in patients with coronarY artery disease; SHIFT, Systolic Heart failure treatment with the If inhibitor ivabradine Trial; TAO, time to 
angina onset; TED, total exercise duration; TLA, time to limiting angina; TST, time to 1 mm ST-segment depression; wk, week.
Table 1 Continued 
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flow was assessed using an intracoronary Doppler tech-
nique at both baseline and after 1 week of treatment 
with ivabradine. The study showed that ivabradine 
improved both hyperaemic and resting coronary flow 
velocity and CFR after 1 week of treatment. These results 
were confirmed by Tagliamonte et al34 in a more recent 
randomised controlled study in 59 stable angina patients. 
They compared the effects of bisoprolol and ivabradine 
on CFR and found that after 1 month of treatment, both 
the ivabradine and bisoprolol patient groups showed an 
increase in CFR, although the increment was larger in the 
ivabradine group than in the bisoprolol group (3.52±0.64 
vs 3.35±0.70, respectively; P<0.01), despite that these 
agents caused a similar reduction in heart rate.
In what could be considered a ‘proof-of-concept’ study, 
Gloekler et al11 assessed the effect of reducing heart rate 
with ivabradine on coronary collateral function. In this 
small-sized, randomised, placebo-controlled study in 46 
patients with stable CAD, mean heart rate a 6-month 
follow-up remained practically unchanged in the placebo 
groupm, that is, +0.2 bpm, whereas it dropped by 8.1 bpm 
in the ivabradine group. Coronary collateral function was 
assessed invasively using a collateral flow index (CFI). CFI 
was similar at baseline and after treatment in the placebo 
group but increased from 0.107±0.077 at baseline to 
0.152±0.090 at 6 months in the ivabradine group (P=0.04). 
In another small ‘proof of concept’ study, Maranta et al35 
showed that in patients with exercise-induced myocardial 
ischaemia treatment with ivabradine reduced the inten-
sity and duration of postischaemic stunning.
In another large trial in patients with stable angina, the 
REDUCTION (Reduction of ischemic events by reduc-
tion of heart rate in the treatment of stable angina with 
ivabradine) study36 (n=4954), ivabradine was well toler-
ated and improved angina symptoms. Symptom improve-
ment was associated with a reduction of heart rate (from 
82.9 bpm to 70.4 bpm) (P<0.0001). Daily life angina 
attacks were reduced by ivabradine from 2.4/week to 0.4/
week (P<0.0001). As a result, use of short-acting nitrates 
in the ivabradine group decreased from 3.3 to 0.6 units/
week.
Ivabradine in combination therapy in angina
Additional anti-ischaemic benefits have been observed 
with ivabradine in patients who were already receiving 
standard therapy with beta-blockers.37 38 48 Evaluation 
of the Antianginal efficacy and Safety of the aSsocia-
tion Of the If Current Inhibitor ivAbradine with a beTa-
blockEr (ASSOCIATE)—a double-blind, randomised, 
multicentre, placebo-controlled trial—study enrolled 
889 patients with stable angina37 and a positive exercise 
stress test despite treatment with atenolol 50 mg once 
daily. ASSOCIATE study randomised patients to receive 
placebo (n=440) or ivabradine (n=449) 5 mg twice daily 
for 2 months, which was then increased to 7.5 mg twice 
daily for two further months. Patients underwent exercise 
testing at 2 months and 4 months of follow-up. In the 
ivabradine group, heart rate decreased by 7 bpm during 
the first 2 months of treatment with 5 mg twice daily and 
by 9 bpm with ivabradine 7.5 mg twice daily. Patients in 
the ivabradine group showed a significant increase in 
total exercise time and all other exercise test criteria such 
as time to limiting angina, time to angina onset and time 
to 1 mm ST-segment depression (P<0.001) compared 
with patients receiving placebo (figure 2).37 This 
improvement was dose dependent with greater benefi-
cial effects observed in patients receiving 7.5 mg twice 
daily compared with those on 5 mg twice daily. Ivabradine 
was well tolerated, and 90% of patients were uptitrated 
to 7.5 mg twice daily after the first 2 months. This study 
demonstrated that in patients with stable angina receiving 
anti-ischaemic therapy with the beta-blocker atenolol the 
addition of ivabradine resulted in a significant long-term 
improvement in exercise induced myocardial ischaemia.
Another large, multicentre, open-label study assessed 
the effects of combined therapy with ivabradine and beta-
blockers over a 4-month period. The prActical Daily effi-
cacy anD safety of procoralan In combinaTION with beta 
blockerS (ADDITIONS) trial recruited 2330 patients with 
stable angina pectoris who were receiving beta-blockers 
and initiated treatment with ivabradine 5 mg or 7.5 mg 
twice daily.38 ADDITIONS showed that combined therapy 
with ivabradine and a beta-blocking agent reduced heart 
rate (from 85 bpm to 65.6 bpm), angina attacks per week 
(from 1.7 to 0.3) and nitrate consumption from 2.3 to 
0.4 per week (all P<0.0001).38 The addition of ivabradine 
was associated with improved QOL, as assessed by EQ-5D 
index scores (P<0.0001).38
In 2007, López-Bescós et al assessed 386 patients with 
chronic stable angina receiving concomitant therapy 
with antianginal therapies such as long-acting nitrates, 
molsidomine, nicorandil, trimetazidine or dihydropyri-
dine calcium channel blockers.29 The efficacy and toler-
ability of different dosages of ivabradine was assessed in 
this study that demonstrated that ivabradine was well 
tolerated, and treatment efficacy was maintained for over 
12 months. Both the 5 mg and 7.5 mg ivabradine doses 
reduced resting heart rate (from 72.4 to 62.7 bpm and 
from 71.8 to 59.4 bpm, respectively), and the number of 
angina attacks per week (P<0.001), with >80% of patients 
having just one or no angina after 12 months of ivabra-
dine therapy, compared with 58% of patients at study 
onset.29
A recent analysis39 of pooled data from three obser-
vational clinical studies in 8555 patients with stable 
angina who received 2.5 mg, 5 mg or 7.5 mg twice daily 
of ivabradine for 4 months showed that therapy with 
ivabradine was associated with a significant reduction in 
the frequency of angina attacks and a significant (87%) 
reduction in the use of short-acting nitrates (P<0.0001). 
An interesting finding in the study was that compared 
with data at baseline—when only 27% of patients were 
in Canadian Cardiovascular Society (CCS) class I—67% 
were in class I at the end of the study 4 months later. 
Furthermore, the proportion of patients in higher class 
severity was reduced from 53% at baseline to 29% for 
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class II and from 20% to 4% in class III/IV. Ivabradine 
had a good safety profile in this study.
In another observational prospective study in 2403 
patients with stable angina, Zarifis et al showed that 
4-month therapy with ivabradine (5 mg uptitrated to 
7.5 mg twice daily reduced resting heart rate from 81.5 
bpm to 63.9 bpm (P<0.001), mean number of anginal 
attacks from 2.0 to 0.2 per week (P<0.001) and sublingual 
nitroglycerin use from 1.4 to 0.1 per week (P<0.001).40 
As in other studies mentioned above, drug compliance 
was high (96%), and the percentage of patients in CCS 
class I angina increased from approximately 38% to 84% 
(P<0.001). Quality of life also improved significantly 
(P<0.001).40
Based on the above antianginal and anti-ischaemic 
efficacy of ivabradine, this agent has been approved 
for treatment of stable angina pectoris for patients in 
sinus rhythm and a heart rate ≥70 bpm whose symptoms 
are inadequately controlled by optimal doses of beta-
blockers, cannot tolerate beta-blockers or have contrain-
dications for the use of beta-blockers.
Ivabradine was shown to be as effective as tradition-
ally used antianginals, such as beta-blockers or calcium 
channel blockers, as shown in two randomised clinical 
trials including ~2000 patients.28 32 The efficacy of ivabra-
dine was also shown in patients receiving combination 
therapy,37 which is usually needed for the majority of 
patients. A recently published consensus41 highlighted 
that currently available antianginal treatments have 
similar levels of efficacy, and therefore choice of therapy 
in the individual patient should be based on patient 
comorbidities and the mechanisms underlying angina 
in a given individual. Tolerability and other pharmaco-
logical properties should be taken into account together 
with the patient’s comorbidities.
effects of ivabradine in special angina patient subgroups
Elderly patients with angina
Elderly patients with angina represent a growing popula-
tion of stable angina patients and pose major challenges 
to treatment. These patients have a higher prevalence 
of comorbidities and frequently develop undesirable 
side effects with the use of antianginal agents or intol-
erance to certain compounds. Ivabradine has been 
shown to have beneficial antianginal effects in elderly 
patients,42 43 patients with comorbidities26 (eg, diabetes44) 
and postrevascularisation angina patients.45–47 In patients 
over 80 years of age, the REDUCTION study showed that 
ivabradine was effective.42 This was an open-label, multi-
centre, non-interventional subanalysis of 382 patients 
with stable angina pectoris taking ivabradine that showed 
that ivabradine therapy over 4 months significantly 
reduced angina pectoris episodes, heart rate and the use 
of nitrates (all P<0.0001 vs baseline).42 This was a rela-
tively small size study, and its results require confirmation 
in larger, double blind, placebo-controlled studies.
The effect of ivabradine (mean study dose 11.61±3.18 mg 
per day) on angina symptoms and QOL was assessed in 
479 patients ≥75 years of age in the ADDITIONS trial. 
The study also evaluated the tolerability of ivabradine 
when combined with beta-blockers.43 After 4 months of 
treatment, the administration of ivabradine was associ-
ated with a reduced heart rate and a reduction of both 
the number of angina attacks per week and the use of 
short-acting nitrates in this elderly population. CCS grade 
distribution and quality of life also improved significantly 
(P<0.0001). Tolerability of treatment with ivabradine in 
the elderly population was rated as very good by 72% and 
as ‘good’ by 28% of physicians.43
patiens with comorbidities
Ivabradine has been shown to be effective in patients 
with stable angina and various concomitant diseases.26 
Pooled data from five randomised studies in patients with 
angina (n=2425) and comorbidities showed that ivabra-
dine had antianginal effects irrespective of age, gender or 
angina severity. The efficacy of ivabradine was confirmed 
in the presence of comorbidities including asthma, 
chronic obstructive pulmonary disease, diabetes mellitus 
and peripheral vascular disease.26 Similar results were 
obtained in a pooled analysis of observational studies in 
8555 patients.39 Ivabradine had comparable antianginal 
efficacy in the elderly, in women, in patients with diabetes 
and in patients with other comorbidities. In different 
randomised controlled trials,44 a total of 535 patients with 
stable angina and diabetes, ivabradine improved exercise 
capacity to a similar extent as that in patients without 
diabetes and was not associated with adverse effects on 
glucose metabolism.44 Data derived from observational 
study, although important, require further confirmation 
by controlled trials.
patients with angina after myocardial revascularisation
Ivabradine was effective in patients with angina who had 
undergone coronary revascularisation.45–47 In a post hoc 
analysis from ADDITIONS45 in 1193 patients with angina 
and history of PCI treated with ivabradine 5.0 mg or 
7.5 mg twice daily for 4 months, the number of angina 
attacks was reduced from 1.9±2.4 per week to 0.5±1.5 
per week and the frequency of nitrate consumption fell 
from 2.7±3.7 per week to 1.0±1.9 per week (P<0.0001). 
Moreover, a post hoc analysis from the Panhellenic 
study46 involving 926 stable angina patients with a history 
of coronary revascularisation who received treatment 
with ivabradine for 4 months showed that this pharma-
cological agent reduced the number of anginal attacks 
from 2.2±2.3 per week to 0.3±0.6 per week (P<0.001), 
nitroglycerin consumption from 1.5±2.2 per week to 
0.1±0.4 per week (P<0.001) and improved QOL, 
compared with baseline (P<0.001).
Heart Rate reduction by IVabradine for improvement 
of ENDothELial function in patients with coronary artery 
disease (RIVENDEL), a relatively small size prospective, 
randomised, controlled open-label study,47 in 70 patients 
who underwent successful PCI assessed the effect of 
ivabradine on brachial artery reactivity, as assessed by 
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flow-mediated dilatation (FMD) and nitroglycerin-me-
diated dilatation (NMD). A significant reduction was 
observed in the ivabradine group at both 4 weeks and 
8 weeks, respectively, in heart rate (65.2±5.9 bpm and 
62.2±5.7 bpm; P<0.001), associated with improvement 
of FMD (12.2%±6.2% and 15.0%±7.7%; P<0.001) and 
enhancement of NMD (16.6%±10.4% and 17.7±10.8; 
P<0.001) compared with standard therapy.47
Data derived from post hoc analysis, or using surrogate 
endpoints, although reflecting important findings in real 
life medical practice, need to be interpreted with caution.
Ivabradine in stable Cad without heart failure
In addition to the assessment of antianginal efficacy, the 
role of ivabradine in prevention of cardiovascular events 
was evaluated in the Study assessInG the morbidity-mor-
tality beNefits of the If inhibitor ivabradine in  patients 
with coronarY artery disease (SIGNIFY) trial.
SIGNIFY trial assessed whether heart rate reduction 
with ivabradine would improve clinical outcomes in 
patients with stable CAD.48 SIGNIFY was a randomised, 
double-blind, placebo-controlled trial of ivabradine given 
on top of standard antianginal therapy, involving 19 102 
patients without clinically apparent heart failure, and a 
baseline heart rate ≥70 bpm. The study also included 12 
049 patients with effort-limiting angina (CCS class ≥II)). 
Patients were randomised to placebo or ivabradine 
(up to 10 mg twice daily to achieve a target heart rate 
of 55–60 bpm). A composite of death from cardiovas-
cular causes or non-fatal myocardial infarction was the 
primary endpoint. At 3 months, the mean (±SD) heart 
rate in the ivabradine group was 60.7±9.0 bpm versus 
70.6±10.1 bpm in the placebo group. After 27.8 months 
(median follow-up), there was no significant difference 
in the primary endpoint (6.8% and 6.4%, respectively; 
HR 1.08; 95% CI 0.96 to 1.20; P=0.20) as well as no signif-
icant difference in the incidence of death from cardio-
vascular causes or non-fatal myocardial infarction. As 
reported by the SIGNIFY investigators, the main finding 
in the study was that ‘among patients who had stable CAD 
without clinical heart failure, the addition of ivabradine 
to standard background therapy to reduce the heart rate 
did not improve clinical outcomes’.48
There was also a significant interaction between the 
effects of ivabradine and the presence of angina (CCS 
class ≥II) at baseline. In that subgroup, ivabradine 
increased the absolute risk of the primary composite 
endpoint of death from cardiovascular causes or non-fatal 
myocardial infarction by 1.1%.48 These unexpected find-
ings were most likely the result of the use of larger than 
recommended ivabradine dosages and combination 
therapy with other heart rate-lowering drugs such as 
verapamil. Following intense data analysis and scrutiny, 
the European Medicines Agency concluded that the risk/
benefit ratio of ivabradine for reducing the symptoms 
of angina remained positive, provided that ivabradine 
is administered at the usual dosage of 5 mg twice daily 
and uptitrated to 7.5 mg twice daily, it is not given in 
combination with verapamil or diltiazem and it is used in 
angina patients in sinus rhythm with a heart rate ≥70 bpm 
who remain symptomatic despite antianginal therapy.51
Ivabradine in stable angina with lvsd
In 2011, Amosova et al assessed in 29 patients with stable 
angina and moderate LV dysfunction the effects and 
tolerability of the combined use of ivabradine and biso-
prolol compared with a strategy that involved uptitrating 
the dose of bisoprolol alone. Ivabradine (7.5 mg twice 
daily) in combination with the beta-blocker bisoprolol 
(5 mg once daily) showed greater efficacy and tolera-
bility than the uptitration of bisoprolol from 5 mg/day to 
10 mg/day.49 After 2 months of treatment, resting heart 
rate decreased similarly in both patient groups. However, 
patients in whom ivabradine was added to bisoprolol 
showed greater improvement in exercise capacity, that is, 
the 6 min walking test (from 388 m to 446 m (P<0.001) 
vs from 386 m to 400 m (P=0.216)) and exercise stress 
testing. Of importance, workload increased significantly 
with ivabradine, from 5.9 to 7.0 metabolic equivalents 
(P=0.004), but not with bisoprolol uptitration (from 5.7 
to 6.2 metabolic equivalents; P=0.141). These results, 
which suggest that the combination of ivabradine and a 
beta-blocker is preferable to beta-blocker uptitration in 
patients with stable angina,49 should be interpreted with 
caution given the small study size. The findings should be 
deemed hypothesis generating.
The randomised, double-blind, placebo-controlled 
BEAUTIFUL study assessed the effects of ivabradine—
given in addition to standard antianginal treatment—in 
10 917 patients with CAD and LV ejection fraction (LVEF) 
<40%.52 53 Patients were randomised to receive ivabradine 
5.0–7.5 mg twice daily or placebo on top of non-prespec-
ified guideline-recommended cardiovascular treatment. 
The primary endpoint was a composite of cardiovascular 
death, hospitalisation for acute myocardial infarction or 
new-onset or worsening heart failure. This incidence of 
the primary endpoint did not differ in the ivabradine 
group compared with the placebo group. A post hoc 
analysis of the BEAUTIFUL trial, however, in patients 
whose limiting symptom at baseline was angina (n=1507) 
showed that ivabradine reduced the primary composite 
endpoint by 24% (HR 0.76; 95% CI 0.58 to 1.00; P=0.05) 
and the rate of hospitalisation for myocardial infarction 
by 42% (HR 0.58; 95% CI 0.37 to 0.92; P=0.021).50
In 6558 patients with symptomatic chronic heart failure 
(CHF), LV systolic dysfunction (LVEF ≤35%) and a heart 
rate of 70 bpm or higher, Systolic Heart failure treatment 
with the If inhibitor ivabradine Trial (SHIFT) was carried 
out to assess the effect of ivabradine on clinical outcomes 
in this patient population. As reported by Swedberg et al, 
SHIFT was a ‘randomized, double-blind, parallel-group, 
multicentre, placebo-controlled study that investigated 
the effects of ivabradine (initiated at 5 mg twice daily and 
titrated to a maximum of 7.5 mg twice daily) when added 
to current guideline-based therapy’.54 55 The primary 
endpoint of SHIFT was a composite of cardiovascular 
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mortality or hospitalisation for worsening heart failure, 
and the median follow-up was 22.9 months. Ivabradine 
significantly reduced the risk of cardiovascular death 
and hospitalisation due to worsening heart failure 
by 18% (29% vs 24%; HR 0.82; 95% CI 0.75 to 0.90; 
P<0.0001), compared with placebo.55 56 A post hoc anal-
ysis of SHIFT carried out in 2220 stable angina patients 
with CHF showed that ivabradine improved cardiovas-
cular outcomes in the angina subgroup.51 Ivabradine 
also reduced the composite endpoint of CV death and 
heart failure hospitalisation by 15%, 20% and 18% in the 
respective subgroups (P for interaction=0.52).56
fIxed-dose CombIned therapy: new perspeCtIves
As discussed in previous sections in the present manu-
script, several studies in patients with stable angina have 
demonstrated the antianginal efficacy of the If inhib-
itor ivabradine when given as monotherapy and also in 
combination with beta-blockers, particularly with meto-
prolol or carvedilol.38 40 57–59 The combination of ivabra-
dine and beta-blockers is well tolerated, and the addition 
of ivabradine does not affect the dosage of beta-blockers 
that can be used. Ivabradine combined with metoprolol 
significantly decreased angina symptoms and the use of 
sublingual nitroglycerin in patients with stable angina 
and CAD leading to improved QOL.57 58
In 1376 patients with angina treated with ivabradine 
and metoprolol, this combination reduced weekly angina 
attacks and nitrate consumption and improved QOL. The 
EQ-5D index and visual analogue scale scores rose from 
0.68±0.27 mm to 0.84±0.20 mm and from 58.1±18.4 mm to 
72.2±15.5 mm, respectively).57 The combined use of 
ivabradine and metoprolol was well tolerated. In terms 
of safety, there was a low rate of reported adverse events, 
with only one patient experiencing the presence of 
phosphenes and only one experiencing symptomatic 
bradycardia with palpitations. About a third (30.3%) of 
previously uncontrolled patients attained a heart rate of 
55–60 bpm.
In a different study,58 59 ivabradine added to metoprolol 
was shown to improve angina symptoms and QOL in 636 
patients with stable angina. Angina attacks were reduced 
from 2.0/week to 0.2/week (P<0.001) and sublingual 
nitroglycerin use reduced from 1.4 times/week to 0.1 
times/week (P<0.001). In this study, percentage of 
patients in CCS angina class III or IV decreased from 
15.4% to 1.9% (P<0.001). The improvement of symptoms 
and angina class led to a significant 14.7-point increase 
in EQ-5D questionnaire score (P<0.001). Adherence to 
treatment was high (98%) throughout the duration of 
the study.
Results such as those described above with the use of 
both ivabradine and beta-blockers provided the rationale 
for the development of fixed-dose combination tablets. 
Two different formulations of ivabradine and beta-
blockers are currently available in clinical practice, that 
is, Implicor (ivabradine and metoprolol) and Carivalan, a 
combination of ivabradine and carvedilol is now available 
in clinical practice. These types of formulation are likely 
to improve adherence to treatment.
Indeed, the recent European Society of Cardiology 
guidelines on heart failure recommend ivabradine as 
the antianginal of choice together with beta-blockers, in 
this setting.60 The use of fixed-dose combination treat-
ments is known to be associated with significant reduc-
tion in the risk of non-adherence when compared with 
non-fixed combination regimens.61 Fixed-dose combina-
tions improve treatment adherence over the long term 
compared with individual treatments taken separately.62 
Of interest, an analysis of SHIFT data demonstrated that 
2596 patients receiving treatment with carvedilol with 
ivabradine had lower rates of the primary composite 
study endpoint, that is, CV death or hospitalisation 
for heart failure (HR 0.80; 95% CI 0.68 to 0.94), heart 
failure hospitalisation (HR 0.73; 95% CI 0.61 to 0.88) 
and cardiovascular hospitalisation (HR 0.80; P=0.002).63 
Hence, the combination of these two agents may prove 
useful in heart failure.
therapeutIC IndICatIons, doses and sIde effeCts
Ivabradine has been assessed in numerous clinical trials 
involving over 45 000 participants and is currently indi-
cated for the symptomatic treatment of chronic stable 
angina pectoris in adults who are in sinus rhythm and 
with a baseline heart rate ≥70 bpm (box 1). Ivabradine is 
also indicated in adults with angina pectoris who cannot 
take beta-blockers and in individuals whose symptoms 
are inadequately controlled by optimal dose beta-blocker 
therapy.64 The mechanism of action, dosages (starting, 
maintenance and uptitration), discontinuation, common 
side effects, precautions and contraindications of ivabra-
dine are also summarised in box 1.
Treatment with ivabradine may be particularly benefi-
cial in angina patients with concomitant CHF. Ivabradine 
is also indicated for treatment of New York Heart Associa-
tion class II–IV CHF with systolic dysfunction, in patients 
in sinus rhythm with a heart rate ≥75 bpm, in combination 
with standard therapy (including beta-blocker therapy) 
or when beta-blocker therapy is contraindicated or not 
tolerated.
undesirable effects
The most common ivabradine-related adverse reactions 
include phosphenes (luminous visual phenomena) and 
bradycardia, both of which are dose dependent and 
related to the pharmacological actions of this agent 
(box 1).64 Phosphenes—usually of mild to moderate 
intensity—have been reported in 14.5% of patients 
and are usually triggered by sudden variations in light 
intensity. They generally occur within 2 months of treat-
ment initiation, after which they may occur repeatedly. 
However, symptoms have very rarely led to patient with-
drawal in trials. In a middle-term randomised clinical 
trial,37 phosphenes were reported by 2% of patients. In 
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a long-term study in patients with stable CAD,52 the use 
of ivabradine in 5477 patients (8893 patient years) was 
associated with visual disorders in 2% of patients (1.29 
patient years). In this study, only 0.3% of patients with-
drew because of symptoms, and symptoms disappeared 
after discontinuation of the treatment.
Severe bradycardia was reported by 3.3% of patients, 
particularly during the first 2–3 months of treatment. 
Severe bradycardia (≤40 bpm) was reported by approx-
imately 0.5% of patients. In SIGNIFY,48 atrial fibrilla-
tion was observed in 5.3% of patients taking ivabradine 
compared with 3.8% in the placebo group. In a pooled 
analysis of more than 40 000 patients from all the phase 
2/3 double-blind controlled clinical trials with a dura-
tion ≥3 months, the incidence of atrial fibrillation was 
4.86% in ivabradine-treated patients versus 4.08% in 
controls, corresponding to a HR of 1.26% and 95% CI of 
1.15 to 1.39.
ConClusIon
In many clinical trials in patients with angina, ivabra-
dine, given as monotherapy or in combination with beta-
blockers, has been shown to have antianginal and anti-is-
chaemic effects and to improve QOL. Evidence from 
the large development programme in angina and data 
from observational studies in daily practice show that 
ivabradine improves angina symptoms regardless of age, 
gender, severity of angina, revascularisation status, history 
of previous myocardial infarction, peripheral vascular 
disease or diabetes. In angina patients with CHF and 
LVSD, the use of ivabradine improves prognosis, reduces 
recurrent hospitalisations and improves QOL. Taken 
together, the beneficial effects of ivabradine on myocar-
dial ischaemia and ventricular function, as summarised 
in this manuscript, suggest that ivabradine represents a 
box 1 Continued
pretreatment resting heart rate <70 bpm
cardiogenic shock
acute myocardial infarction
severe hypotension (<90/50 mm Hg)
severe hepatic insufficiency
sick sinus syndrome
sinoatrial block
unstable/acute heart failure
pacemaker dependence
unstable angina
atrioventricular block (third degree)
concomitant treatment with strong CYP3A4 inhibitors (eg, azoles, 
macrolide antibiotics, HIV protease inhibitors and nefazodone)
concomitant use of calcium channel blockers that reduce heart 
rate (ie, verapamil, diltiazem) that moderately inhibit CYP3A4
pregnancy/lactation/women of childbearing potential not using 
contraceptive measures.
bpm, beats per minute.
box 1 Treatment with ivabradine in chronic stable angina
use of ivabradine in chronic stable angina
Indication
symptomatic treatment of chronic stable angina pectoris 
in adult patients:
with normal sinus rhythm
with heart rate ≥70 bpm
in combination with beta-blockers in patients inadequately 
controlled with optimal beta-blocker therapy or in patients with a 
beta-blocker intolerance or contraindication.
mechanism of action
Selective and specific inhibition of the cardiac pacemaker If current 
that controls the spontaneous diastolic depolarisation in the sinus 
node and regulates heart rate.
starting dosage
<75 years: 5 mg twice daily
≥75 years: 2.5 mg twice daily
renal impairment: no dose adjustment with renal insufficiency or 
creatinine clearance>15 mL/min
hepatic impairment: mild (no dose adjustment), moderate (caution) 
and severe (contraindicated).
uptitration
Uptitration to next highest dose is possible after 3–4 weeks if:
initial dose is well tolerated
symptoms persist
Heart rate >60 bpm.
maintenance dose
≤7.5 mg twice daily.
discontinuation
no symptomatic response within 3 months
persistent bradycardia (heart rate <50 bpm) or bradycardic 
symptoms (ie, dizziness, fatigue or hypotension) after dose 
reduction.
Common side effects
Visual
phosphenes: usually mild/moderate intensity
blurred vision.
Cardiovascular
bradycardia
atrioventricular block (first degree)
atrial fibrillation
ventricular extrasystole
uncontrolled blood pressure.
Other
Headache: during first month of treatment.
precautions
hypotension
atrial fibrillation – cardiac arrhythmias
congenital QT syndrome/QT-prolonging medicines
antihypertensive treatment changes in hypertensive patients
galactose intolerance/Lapp lactase deficiency/glucose-galactose 
malabsorption.
Contraindications
hypersensitivity to active ingredient or excipients
Continued
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useful agent for the symptomatic treatment of patients 
with angina pectoris, especially those with CHF.
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